HHS Secretary Xavier Becerra, CMS Administrator Chiquita Brooks-LaSure Remark on Implementation of Inflation Reduction Act Provision Addressing Medicare Payments for Biosimilars
October 3, 2022 HHS Press Office Immediate Release
By statute, Medicare Part B generally pays 106% of ASP (ASP plus 6%) for separately payable drugs and biologicals furnished in physician offices, hospital outpatient departments, and ambulatory surgical centers, with some exceptions. ASP is calculated based on manufacturers’ sales to all U.S. purchasers minus manufacturer rebates, discounts, and price concessions (with certain exceptions). Manufacturers report ASP data to CMS quarterly.